Pressure Biosciences, Inc. (NASDAQ: PBIO), a life sciences company based in Massachusetts, researches, develops, and commercializes on sample preparation systems. The company’s cornerstone is its pressure cycling technology (PCT) that has the ability to use hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. In layman’s terms, the company’s technology opens the door to further insight into diseases such as obesity, heart disease, diabetes and certain cancers.

The company’s efforts are not only contributing to technological advancement, but are also winning awards. Last month, Pressure Biosciences was awarded the 2007 North American Frost & Sullivan Award for Technology Innovation. The award was given for Pressure Biosciences’ PCT paired with its ProteoSolve-LRS kit.

“Unlike conventional methods of tissue delipidation that comprise several stages such as cell and tissue disruption, protein extraction from lipids, and partitioning, the new PCT-dependent sample preparation approach from Pressure BioSciences combines these complex stages into a single step, as a result of which the fractions of proteins and lipids generated from each sample can be analyzed individually, faster, more efficiently, and with more reproducibility,” Sandhya Kamath, senior research analyst for Frost & Sullivan stated in a recent press release. “Moreover, this approach integrates PCT and reagents to extract and fractionate proteins from lipid-rich tissues in a detergent-free manner.”

While the lingo and technology of the PCT process might be a foreign language to most of us, the diseases that Pressure Biosciences focuses on hits close to home to many Americans. Obesity, heart disease and diabetes are among the nation’s top killers, and Pressure Biosciences has positioned itself to shed light on further research to stop them.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board